Results 111 to 120 of about 50,723 (266)

Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression

PROTEOMICS, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free ...
Ha‐Song Bae, Yun‐Jeong Seo, Eun‐Bi Kim, Hyoung‐Min Park, I‐Hsuan Liu, J. Eugene Lee, Jae‐Young Kim   +6 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Baicalein Sensitizes Radioresistant BT549 and MCF7‐R Breast Cancer Cells by Modulating Rac1 Signaling

Phytotherapy Research, EarlyView.
ABSTRACT Radioresistance remains a key barrier in breast cancer (BC) treatment. Baicalein, a flavonoid from Scutellaria baicalensis, has shown potential to enhance radiosensitivity. This study investigates its efficacy and mechanism in radioresistant BC models. Radioresistant BC cell models were established via fractionated irradiation and validated by
Zitong Zhao, Zhangyun Li, Quanzhou Peng, Shuqun Zhang   +3 more
wiley   +1 more source

Beyond BRCA: A scoping review of person-centred care for women diagnosed with a BRCA gene mutation

BMJ Open
Objectives Women diagnosed with BRCA1/2 mutations face significantly elevated lifetime risks of breast and ovarian cancer. Due to the distinctive biopsychosocial implications of a BRCA diagnosis, the care trajectory for these women is highly personalised, yet their care needs frequently remain unmet.
Leonie Emilia Witte, Cornelia van Diepen, Jane Murray Cramm   +2 more
openaire   +3 more sources

What Happens After Menopause (WHAM)? A Progress Report of a Prospective Controlled Study of Women After Pre‐Menopausal Risk‐Reducing Bilateral Salpingo‐Oophorectomy

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Surgical menopause, the removal of both ovaries prior to natural menopause, may impact short‐and long‐term physical and emotional health. An increasingly common cause of surgical menopause is risk‐reducing salpingo‐oophorectomy (RRSO) in those at high inherited risk of ovarian cancer.
Sarah A. L. Price, Pauline M. Maki, Samar R. El Khoudary, Alison Brand, Rakibul M. Islam, Susan M. Domchek, Hadine Joffe, Gita D. Mishra, Katrina M. Moss, Fiona C. Baker, Sabine Braat, John D. Wark, Martha Hickey   +12 more
wiley   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Presence and prevalence of single nucleotide sequence polymorphisms in TP53 and BRCA2 genes as of cervical and ovarian cancers in women using hormonal contraceptives in Abuja, Nigeria

Journal of Public Health in Africa
Background: Cancer remains a major health burden in sub-Saharan Africa, characterised by high incidence and mortality rates as a result of late diagnosis, limited access to treatment and poor outcomes.
Omorinsola F. Odebiyi, Adedapo Kehinde, Mohammed S. Abdulsalami, Deborah M. Dibal   +3 more
doaj   +1 more source

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew, Pernilla Dahm‐Kähler, Kenny Rodriguez Wallberg, Erik Holmberg, Angelique Flöter‐Rådestad   +4 more
wiley   +1 more source